• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

分析前变量对神经病理学血液生物标志物稳定性的影响。

Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology.

机构信息

Department of Neuroscience, University of Minnesota, Minneapolis, MN, USA.

Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA.

出版信息

J Alzheimers Dis. 2023;95(2):735-748. doi: 10.3233/JAD-230384.

DOI:10.3233/JAD-230384
PMID:37574735
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11520930/
Abstract

BACKGROUND

Sample collection and preanalytical protocols may significantly impact the results of large-scale epidemiological studies incorporating blood-based biomarkers of neuropathology.

OBJECTIVE

To evaluate the stability and assay variability of several blood-based biomarkers of neuropathology for common preanalytical conditions.

METHODS

We collected serum and plasma samples from 41 participants and evaluated the effect of processing delay of up to 72 h when stored at 4∘C, three freeze-thaw cycles, and a combination of 48-h processing delay when stored at 4∘C and three freeze-thaw cycles on biomarker stability. Using the Simoa assay (Quanterix Inc.), we measured amyloid-β 40 (Aβ40), amyloid-β 42 (Aβ42), neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau 181 (p-tau-181).

RESULTS

We found that Aβ40 and Aβ42 levels significantly decreased after a 24-h processing delay in both plasma and serum samples, and a single freeze-thaw cycle (p < 0.0001). Nevertheless, serum Aβ42/40 ratio remained stable with a processing delay up to 48 h while plasma Aβ42/40 ratio showed only small but significant increase with a delay up to 72 h. Both plasma and serum GFAP and NfL levels were only modestly affected by processing delay and freeze-thaw cycles. Plasma p-tau-181 levels notably increased with a 24-, 48-, and 72-h processing delay, but remained stable in serum. Intra-individual variation over two weeks was minimal for all biomarkers and their levels were substantially lower in serum when compared with plasma.

CONCLUSION

These results suggest that standardizing preanalytical variables will allow robust measurements of biomarkers of neuropathology in population studies.

摘要

背景

样本采集和分析前方案可能会显著影响包含神经病理学血液生物标志物的大规模流行病学研究的结果。

目的

评估几种神经病理学血液生物标志物在常见分析前条件下的稳定性和分析变异性。

方法

我们从 41 名参与者中采集血清和血浆样本,并评估了在 4°C 下储存时长达 72 小时的处理延迟、三个冻融循环以及在 4°C 下储存时长达 48 小时的处理延迟与三个冻融循环的组合对生物标志物稳定性的影响。使用 Simoa 分析(Quanterix Inc.),我们测量了淀粉样蛋白-β 40(Aβ40)、淀粉样蛋白-β 42(Aβ42)、神经丝轻链(NfL)、胶质纤维酸性蛋白(GFAP)和磷酸化 tau 181(p-tau-181)。

结果

我们发现,在血浆和血清样本中,24 小时的处理延迟后 Aβ40 和 Aβ42 水平显著下降,且单个冻融循环也会降低(p<0.0001)。然而,血清 Aβ42/40 比值在 48 小时的处理延迟内保持稳定,而血浆 Aβ42/40 比值在 72 小时的处理延迟内仅略有增加但具有统计学意义。处理延迟和冻融循环仅对血浆和血清中的 GFAP 和 NfL 水平有适度影响。血浆 p-tau-181 水平在 24、48 和 72 小时的处理延迟后显著增加,但在血清中保持稳定。所有生物标志物的个体内两周内的变异均较小,且与血浆相比,其水平在血清中显著降低。

结论

这些结果表明,标准化分析前变量将允许在人群研究中对神经病理学生物标志物进行稳健的测量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/15309b022232/nihms-2029314-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/47a7d52bad28/nihms-2029314-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/c9bcb0b69fa2/nihms-2029314-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/bcdd47e8c8a0/nihms-2029314-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/ef2d9ed17ccf/nihms-2029314-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/089329cb6358/nihms-2029314-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/15309b022232/nihms-2029314-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/47a7d52bad28/nihms-2029314-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/c9bcb0b69fa2/nihms-2029314-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/bcdd47e8c8a0/nihms-2029314-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/ef2d9ed17ccf/nihms-2029314-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/089329cb6358/nihms-2029314-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d28e/11520930/15309b022232/nihms-2029314-f0006.jpg

相似文献

1
Pre-Analytical Variables Influencing Stability of Blood-Based Biomarkers of Neuropathology.分析前变量对神经病理学血液生物标志物稳定性的影响。
J Alzheimers Dis. 2023;95(2):735-748. doi: 10.3233/JAD-230384.
2
Short-term variability of Alzheimer's disease plasma biomarkers in a mixed memory clinic cohort.混合记忆门诊队列中阿尔茨海默病血浆生物标志物的短期变异性
Alzheimers Res Ther. 2025 Jan 21;17(1):26. doi: 10.1186/s13195-024-01658-7.
3
The impact of pre-analytical factors on plasma biomarkers for Alzheimer's disease: The ASPREE Healthy Ageing Biobank.分析前因素对阿尔茨海默病血浆生物标志物的影响:ASPREE健康老龄化生物样本库
J Prev Alzheimers Dis. 2025 Apr;12(4):100058. doi: 10.1016/j.tjpad.2025.100058. Epub 2025 Feb 12.
4
Olfaction and Plasma Biomarkers of Alzheimer Disease and Neurodegeneration in the Atherosclerosis Risk in Communities Study.社区动脉粥样硬化风险研究中阿尔茨海默病和神经退行性变的嗅觉与血浆生物标志物
Neurology. 2025 Jun 10;104(11):e213706. doi: 10.1212/WNL.0000000000213706. Epub 2025 May 15.
5
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study.血浆Aβ42/40比值、磷酸化tau181、胶质纤维酸性蛋白(GFAP)和神经丝轻链(NfL)在阿尔茨海默病和非阿尔茨海默病性痴呆连续病程中的诊断性能:一项国际多中心研究
Alzheimers Dement. 2025 Jun;21(6):e14573. doi: 10.1002/alz.14573.
6
Association of Plasma Biomarkers of Alzheimer Disease and Neurodegeneration With Longitudinal Intra-Network Functional Brain Connectivity.阿尔茨海默病和神经退行性变的血浆生物标志物与纵向脑内网络功能连接的关联
Neurology. 2025 Feb 25;104(4):e210271. doi: 10.1212/WNL.0000000000210271. Epub 2025 Jan 31.
7
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.脑脊液和血液生物标志物在阿尔茨海默病诊断中的应用:系统评价和荟萃分析。
Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8.
8
The ratio of plasma pTau217 to Aβ42 outperforms individual measurements in detecting brain amyloidosis.在检测脑淀粉样变性方面,血浆pTau217与Aβ42的比值比单独测量更具优势。
medRxiv. 2025 Jan 10:2024.12.07.24318640. doi: 10.1101/2024.12.07.24318640.
9
Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks.通过淀粉样蛋白和tau PET时钟评估阿尔茨海默病血浆生物标志物变化的时间。
medRxiv. 2024 Nov 14:2024.10.25.24316144. doi: 10.1101/2024.10.25.24316144.
10
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.脑源性 tau:阿尔茨海默病型神经退行性变的新型基于血液的生物标志物。
Brain. 2023 Mar 1;146(3):1152-1165. doi: 10.1093/brain/awac407.

引用本文的文献

1
Glial fibrillary acidic protein in cerebrospinal fluid in humans is sensitive to various pre-analytical conditions: possible explanation and solution.人脑脊液中的胶质纤维酸性蛋白对多种分析前条件敏感:可能的解释及解决方法。
Front Neurol. 2025 Aug 1;16:1627405. doi: 10.3389/fneur.2025.1627405. eCollection 2025.
2
Differences in Alzheimer's disease blood biomarker stability: Implications for the use of tau/amyloid ratios.阿尔茨海默病血液生物标志物稳定性的差异:对tau/淀粉样蛋白比率应用的启示。
Alzheimers Dement. 2025 Apr;21(4):e70173. doi: 10.1002/alz.70173.
3
Blood-based biomarkers of Alzheimer's disease and incident dementia in the community.

本文引用的文献

1
Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer's disease and frontotemporal lobar degeneration.基于血液和神经生理学标志物在阿尔茨海默病和额颞叶变性鉴别诊断中的分类准确性。
Alzheimers Res Ther. 2022 Oct 13;14(1):155. doi: 10.1186/s13195-022-01094-5.
2
Plasma β-amyloid, tau, neurodegeneration biomarkers and inflammatory factors of probable Alzheimer's disease dementia in Chinese individuals.中国个体中可能患有阿尔茨海默病痴呆症的血浆β-淀粉样蛋白、tau蛋白、神经退行性变生物标志物及炎症因子
Front Aging Neurosci. 2022 Aug 18;14:963845. doi: 10.3389/fnagi.2022.963845. eCollection 2022.
3
社区中阿尔茨海默病及新发痴呆症的血液生物标志物
Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03605-x.
4
Short-term variability of Alzheimer's disease plasma biomarkers in a mixed memory clinic cohort.混合记忆门诊队列中阿尔茨海默病血浆生物标志物的短期变异性
Alzheimers Res Ther. 2025 Jan 21;17(1):26. doi: 10.1186/s13195-024-01658-7.
Blood GFAP as an emerging biomarker in brain and spinal cord disorders.
血液 GFAP 作为脑和脊髓疾病的新兴生物标志物。
Nat Rev Neurol. 2022 Mar;18(3):158-172. doi: 10.1038/s41582-021-00616-3. Epub 2022 Feb 3.
4
Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.阿尔茨海默病相关血液生物标志物检测前样本处理影响的特征分析:来自阿尔茨海默病血液生物标志物标准化(SABB)工作组的结果。
Alzheimers Dement. 2022 Aug;18(8):1484-1497. doi: 10.1002/alz.12510. Epub 2021 Nov 29.
5
Cross sectional association between cytomegalovirus seropositivity, inflammation and cognitive impairment in elderly cancer survivors.巨细胞病毒血清阳性、炎症与老年癌症幸存者认知障碍的横断面相关性。
Cancer Causes Control. 2022 Jan;33(1):81-90. doi: 10.1007/s10552-021-01504-3. Epub 2021 Oct 12.
6
Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances.基于血液的β-淀粉样蛋白和磷酸化 tau 的高灵敏度测量作为阿尔茨海默病的生物标志物:对最新进展的重点综述。
J Neurol Neurosurg Psychiatry. 2021 Nov;92(11):1231-1241. doi: 10.1136/jnnp-2021-327370. Epub 2021 Sep 11.
7
It's not 'just a tube of blood': principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies.并非“仅仅一管血”:免疫疗法研究中基于血液的生物标志物的方案制定、样本采集、人员配备和预算考虑的原则。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-003212.
8
Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration.分析前程序对阿尔茨海默病病理生理学、神经胶质细胞激活和神经退行性变血液生物标志物的影响。
Alzheimers Dement (Amst). 2021 Jun 2;13(1):e12168. doi: 10.1002/dad2.12168. eCollection 2021.
9
Seven day pre-analytical stability of serum and plasma neurofilament light chain.血清和血浆神经丝轻链的 7 天预分析稳定性。
Sci Rep. 2021 May 26;11(1):11034. doi: 10.1038/s41598-021-90639-z.
10
Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.多民族社区研究中的血浆 p-tau181、p-tau217 和其他基于血液的阿尔茨海默病生物标志物。
Alzheimers Dement. 2021 Aug;17(8):1353-1364. doi: 10.1002/alz.12301. Epub 2021 Feb 13.